AMTX vs NEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMTX exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile operational foundation. The absence of an Altman Z-Score and negative profitability metrics—especially a -38.96% profit margin and -8.96% ROA—signal severe operational distress. Despite a 14.2% YoY revenue growth and recent positive EPS surprises, the company remains unprofitable with negative cash flow and extreme liquidity issues (current ratio of 0.07). The stock trades at a price/sales of 0.77, but this is misleading given the lack of sustainable earnings and deteriorating balance sheet. The 52-week price range of $1.22–$3.66 reflects high volatility and speculative risk.
NEM shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 155.7% premium to fair value estimate ($44.73), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
AMTX vs NEM: Head-to-Head Comparison
This page compares Aemetis, Inc. (AMTX) and Newmont Corporation (NEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.